Evidence map›Paper›PMID 41481469›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

A neutralizing APOA5 monoclonal antibody reduces amounts of lipoprotein lipase in capillaries and triggers hypertriglyceridemia.

Ye Yang, Anne P Beigneux, Troy L Lowe, Yan Q Chen, Katherine Xie, Hyesoo Jung, Yiping Tu, Rachel G Yu, Julia L Scheithauer, Shailen Mehta and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ye Yang *Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.ORCID 0000-0003-4260-7700
Anne P Beigneux *Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.ORCID 0000-0002-7892-150X
Troy L LoweDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.
Yan Q ChenLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.ORCID 0000-0001-9311-6077
Katherine XieDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.
Hyesoo JungDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.ORCID 0000-0002-6343-4338
Yiping TuDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.ORCID 0000-0002-4630-9113
Rachel G YuDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.
Julia L ScheithauerDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.
Shailen MehtaDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.
Jerry WuDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.
Lindsay AlvarezDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.
W Sean DavidsonDepartment of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267.ORCID 0000-0003-2756-2989
Gabriel BirraneDivision of Experimental Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215.ORCID 0000-0002-1759-5499
Alan T RemaleyLaboratory of Lipoprotein Metabolism, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20814.
Denis SviridovLaboratory of Lipoprotein Metabolism, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20814.
Michael PlougFinsen Laboratory, Copenhagen University Hospital-Rigshospitalet, Copenhagen N DK-2200, Denmark.ORCID 0000-0003-2215-4265
Eugene Y ZhenLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.ORCID 0000-0002-0162-5665
Yuewei QianLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.ORCID 0000-0003-0584-4723
John H SloanLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.
Robert W SiegelLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.ORCID 0000-0002-0833-5580
Robert J KonradLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.ORCID 0000-0003-0923-0542
Loren G FongDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.ORCID 0000-0002-4465-5290
Stephen G YoungDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095.ORCID 0000-0001-7270-3176

Funding

Refining Physiologic Mechanisms for Intravascular Triglyceride MetabolismR01HL087228 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEIGNEUX, ANNE, FONG, LOREN GI · 2007 to 2024
$7.8M
Regulation of Intravascular Triglyceride HydrolysisR35HL176438 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Stephen G. Young · 2025 to 2026
$2.2M
The roles of apolipoprotein A-IV structure and lipid affinity in its functionR01HL082734 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN · 2006 to 2009
$1.2M
Fondation Leducq (Leducq Foundation) 12CVD04 23CVD02HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL146358 HL087228 HL139725 HL176438NHLBI NIH HHS R01 HL082734NHLBI NIH HHS R01 HL087228NHLBI NIH HHS R35 HL176438Novo Nordisk Foundation Center for Basic Metabolic Research (NovoNordisk Foundation Center for Basic Metabolic Research) NNF20OC0063444The John and Birthe Meyer Foundation 000
6 · The paper itself

Abstract

Apolipoprotein AV (APOA5) regulates intravascular triglyceride metabolism by binding to the angiopoietin-like protein 3/8 complex (ANGPTL3/8) and suppressing its ability to unfold the native conformation of lipoprotein lipase (LPL). LPL unfolding results in loss of catalytic activity and the detachment of LPL from the surface of cells. An

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingApolipoprotein A-VApolipoproteins AHypertriglyceridemiaLipoprotein LipaseAngiopoietin-Like Protein 3Angiopoietin-like ProteinsAnimalsHumansMaleMiceMice, KnockoutTriglyceridesAngiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanAntibodies, MonoclonalAntibodies, NeutralizingAPOA5 protein, humanApoa5 protein, mouseApolipoprotein A-VApolipoproteins ALipoprotein LipaseTriglycerideshuman Fab bacteriophagehypertriglyceridemialipoprotein lipasemonoclonal Antibodytriglycerides

Identifiers

PMID41481469
PMCPMC12773762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.